StockWatch
·
Biotechnology: Pharmaceutical Preparations
AcquisitionsNov 17, 2026, 09:51 AM

Viatris Completes Pacira BioSciences Acquisition for $1.69B

AI Summary

Viatris Inc. has successfully completed its acquisition of Pacira BioSciences, Inc. for approximately $1.69 billion. The tender offer for Pacira shares, priced at $36.50 per share in cash, expired on November 16, 2026, with Viatris acquiring approximately 66.46% of the outstanding shares. Following the tender offer, Pacira was merged with and into a wholly owned subsidiary of Viatris, making Pacira a subsidiary of Viatris. The acquisition is expected to contribute between $90 million and $100 million in total revenues for the remainder of 2026. Pacira shares will be delisted from the Nasdaq Global Select Market.

Key Highlights

  • Viatris Inc. completed the acquisition of Pacira BioSciences, Inc. for approximately $1.69 billion.
  • The tender offer price was $36.50 per share in cash.
  • Approximately 66.46% of Pacira shares were tendered and accepted for payment.
  • Pacira BioSciences, Inc. will be delisted from the Nasdaq Global Select Market.
  • The acquisition is expected to contribute $90 million to $100 million in revenues for Viatris in 2026.